Compositions and methods of treating facioscapulohumeral muscular dystrophy
US-2024400707-A1 · Dec 5, 2024 · US
Cell penetrating conjugates and methods of use thereof
US10967070B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10967070-B2 |
| Application number | US-201615056777-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 29, 2016 |
| Priority date | Aug 29, 2013 |
| Publication date | Apr 6, 2021 |
| Grant date | Apr 6, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided herein are cell penetrating conjugates. The conjugates include a non-cell penetrating protein attached to a phosphorothioate nucleic acid or phosphorothioate polymer backbone, wherein the phosphorothioate nucleic acid or phosphorothioate polymer backbone enhances intracellular delivery of the non-cell penetrating protein. Also provided are compositions and kits comprising the cojugates.
First claim
Opening claim text (preview).
What is claimed is: 1. An antibody covalently attached to one or more phosphorothioate nucleic acids, wherein the one or more phosphorothioate nucleic acids are independently from 10 to 30 residues in length, wherein the antibody binds an intracellular target and wherein the antibody is non-cell penetrating in the absence of said one or more phosphorothioate nucleic acids. 2. The antibody of claim 1 , wherein each phosphorothioate nucleic acid is independently attached to a lysine, arginine, cysteine, or histidine of the antibody. 3. The antibody of claim 1 , wherein the intracellular target is a target of a disease selected from the group consisting of autoimmune disease, inflammatory disease, metabolic disorder, developmental disorder, cardiovascular disease, liver disease, intestinal disease, infectious disease, endocrine disease, neurological disorder, and cancer. 4. The antibody of claim 1 , wherein the intracellular target is a cancer target. 5. The antibody of claim 1 , wherein the intracellular target is selected from the group consisting of STAT3, exportin 7, and Src. 6. A cell comprising the antibody of claim 1 . 7. A pharmaceutical composition comprising the antibody of claim 1 and a pharmaceutically acceptable carrier. 8. A kit comprising the antibody of claim 1 or the pharmaceutical composition of claim 7 and instructions for use.
Assignees
Inventors
Classifications
- A61K47/6807Primary
the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense · CPC title
- A61K47/6843Primary
the antibody targeting a material from animals or humans · CPC title
Protein; Peptide · CPC title
Sugars, nucleosides, nucleotides or nucleic acids · CPC title
DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity} · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10967070B2 cover?
- Provided herein are cell penetrating conjugates. The conjugates include a non-cell penetrating protein attached to a phosphorothioate nucleic acid or phosphorothioate polymer backbone, wherein the phosphorothioate nucleic acid or phosphorothioate polymer backbone enhances intracellular delivery of the non-cell penetrating protein. Also provided are compositions and kits comprising the cojugates.
- Who is the assignee on this patent?
- Hope City
- What technology area does this patent fall under?
- Primary CPC classification A61K47/6807. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Apr 06 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).